Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Up 1,022.5% in December

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 4,710,000 shares, a growth of 1,022.5% from the December 15th total of 419,600 shares. Based on an average daily trading volume, of 6,840,000 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Separately, Leerink Partners lowered their price objective on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Institutional Trading of Vincerx Pharma

An institutional investor recently raised its position in Vincerx Pharma stock. Marshall Wace LLP boosted its position in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 328,533 shares of the company’s stock after purchasing an additional 256,967 shares during the quarter. Marshall Wace LLP owned about 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. 44.02% of the stock is currently owned by hedge funds and other institutional investors.

Vincerx Pharma Trading Down 5.9 %

Shares of NASDAQ:VINC traded down $0.01 during trading on Monday, reaching $0.18. 1,958,831 shares of the company traded hands, compared to its average volume of 4,464,351. Vincerx Pharma has a 52-week low of $0.18 and a 52-week high of $9.37. The firm has a market capitalization of $6.02 million, a price-to-earnings ratio of -0.17 and a beta of 1.48. The business’s fifty day moving average is $0.25 and its 200-day moving average is $0.49.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.